Retisert (Fluocinolone Acetonide Intravitreal Implant) Drug Information: Medication Guide and Patient Information

Pill Identifier Search

May 27, 2012

Retisert

Uveitis »

Introduction

Uveitis (pronounced you-vee-EYE-tis) is basically an inflammation of the eye. The condition involves all inflammatory processes of the middle layers of the eye, also called the uveal tract or uvea. The uvea includes the iris (colored part of the eye), choroid (a thin membrane containing many blood vessels) and ciliary body (the part of the eye that joins these together).

The uvea is very important because its many veins and arteries transport blood to the parts of the eye that are critical for vision.

Learn more about the structures that make up the eye in the article titled " The Amazing Human Eye ."

What Are the Symptoms of Uveitis?

Symptoms of uveitis may include:

Eye redness and irritation
Blurred vision
Eye pain
Increased sensitivity to light ...

Read the Uveitis article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Retisert

Eye Diseases and Conditions Slideshow Pictures

Pink Eye Slideshow Pictures

Cataracts Slideshow Pictures

font size

PATIENT INFORMATION

Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of RETISERT.

As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place RETISERT into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, temporary decreased visual acuity, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.

Following implantation of RETISERT, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.

Based on clinical trials with RETISERT, within 3 years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure. (see Clinical Trials Experience - Ocular Events section).

Based on clinical trials with RETISERT, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.

Last reviewed on RxList: 8/2/2011
This monograph has been modified to include the generic and brand name in many instances.